journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders

journal
https://www.readbyqxmd.com/read/29998370/characteristics-of-dapagliflozin-responders-a-longitudinal-prospective-nationwide-dapagliflozin-surveillance-study-in-korea
#1
Eugene Han, Ari Kim, Sung Jae Lee, Je-Yon Kim, Jae Hyeon Kim, Woo Je Lee, Byung-Wan Lee
INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings. METHODS: The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10 mg/day) were analyzed (ClinicalTrials...
July 11, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29987647/the-associations-between-paraoxonase-1-l55m-q192r-genetic-polymorphisms-and-the-susceptibilities-of-diabetic-macroangiopathy-and-diabetic-microangiopathy-a-meta-analysis
#2
Chenfang Wu, Diling Wu, Minjie Lin, Yanjun Zhong
INTRODUCTION: Plenty of studies have focused on the associations of paraoxonase 1 Q192R and L55M genetic polymorphisms with diabetic macroangiopathy and microangiopathy susceptibility, but these associations remain controversial. Therefore, this meta-analysis was conducted to demonstrate these relationships. METHODS: Relevant studies published in English or Chinese were identified in PubMed, Embase, Wanfang Database, and CNKI by applying specific inclusion and exclusion criteria...
July 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29971748/switching-from-pre-mixed-insulin-to-regimens-with-insulin-glargine-in-type-2-diabetes-a-prospective-observational-study-of-data-from-adriatic-countries
#3
Goran Petrovski, Dashamir Gjergji, Aleksandra Grbic, Blazenko Vukovic, Mitja Krajnc, Natasa Grulovic
INTRODUCTION: Long-acting insulin analogs such as insulin glargine may offer improved glycemic control in patients with type 2 diabetes (T2D) compared to conventional insulin therapies. The objective of this study was to determine whether switching to insulin glargine had beneficial effects on glycemic control, weight gain, and incidence of hypoglycemia in patients with suboptimally managed T2D. METHODS: This prospective observational study was performed on 1041 patients who were suboptimally controlled on pre-mixed insulin therapy and were switched to an insulin glargine regimen...
July 3, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29961246/glycemic-control-in-hospitalized-patients-with-diabetes-receiving-corticosteroids-using-a-neutral-protamine-hagedorn-insulin-protocol-a-randomized-clinical-trial
#4
Ameer Khowaja, Jamil B Alkhaddo, Zaighum Rana, Lisa Fish
INTRODUCTION: Hospitalized patients with diabetes receiving corticosteroids are at risk of developing hyperglycemia and related complications. This study evaluated a neutral protamine Hagedorn (NPH) insulin-based protocol in improving glycemic control in hospitalized patients receiving corticosteroids. METHODS: This was a randomized, prospective, non-blinded study in an inpatient setting involving patients with diabetes who were hospitalized and receiving prednisone ≥ 10 mg per day or equivalent...
June 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29961245/turkish-insulin-injection-technique-study-population-characteristics-of-turkish-patients-with-diabetes-who-inject-insulin-and-details-of-their-injection-practices-as-assessed-by-survey-questionnaire
#5
Selcuk Dagdelen, Oguzhan Deyneli, Nermin Olgun, Zeynep Osar Siva, Mehmet Sargin, Sükrü Hatun, Mustafa Kulaksizoglu, Ahmet Kaya, Cansu Aslan Gürlek, Laurence J Hirsch, Kenneth W Strauss
INTRODUCTION: Over 7 million people in Turkey have diabetes. Of the 1 million who inject insulin little is known of their habits and injection techniques. METHODS: We conducted an Injection Technique Questionnaire (ITQ) survey throughout Turkey that involved 1376 patients from 56 centers. Turkish values were compared with those from 41 other countries participating in the ITQ, known here as Rest of World (ROW). RESULTS: The majority (50.4%) of Turkish insulin users give four injections/ day as opposed to ROW, where only 30...
June 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29961244/turkish-insulin-injection-techniques-study-complications-of-injecting-insulin-among-turkish-patients-with-diabetes-education-they-received-and-the-role-of-health-care-professional-as-assessed-by-survey-questionnaire
#6
Selcuk Dagdelen, Oguzhan Deyneli, Nermin Olgun, Zeynep Osar Siva, Mehmet Sargin, Sükrü Hatun, Mustafa Kulaksizoglu, Ahmet Kaya, Cansu Aslan Gürlek, Laurence J Hirsch, Kenneth W Strauss
INTRODUCTION: Using the Turkish and rest of world (ROW) Injection Technique Questionnaire (ITQ) data we address key insulin injection complications. METHODS: Summarized in first ITQ paper. RESULTS: Nearly one-third of Turkish insulin users described lesions consistent with lipohypertrophy (LH) at their injection sites and 27.4% were found to have LH by the examining nurse (using visual inspection and palpation). LH lesions in the abdomen and thigh of Turkish patients are slightly smaller than those measured in ROW but more than half of Turkish patients who have LH continue to inject into them at least daily...
June 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29951978/contribution-of-bhg-and-pphg-to-overall-hyperglycemia-in-t2dm-patients-treated-with-lm25-and-lm50-post-hoc-analysis-of-a-randomized-crossover-trial
#7
Wei Li, Fan Ping, Lingling Xu, Huabing Zhang, Yaxiu Dong, Hongmei Li, Qi Sun, Yuxiu Li
INTRODUCTION: To investigate the relative contribution rates of basal hyperglycemia (BHG) and postprandial hyperglycemia (PPHG) to overall hyperglycemia in patients with type 2 diabetes mellitus (T2DM) treated with insulin lispro mix 25 and 50 (LM25 and LM50) as evaluated by continuous glucose monitoring (CGM). METHODS: Eighty-one T2DM patients treated with premixed human insulin 70/30 (PHI70/30) were randomly divided into two groups and received a crossover protocol...
June 27, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29951977/cerebral-biochemical-effect-of-pregabalin-in-patients-with-painful-diabetic-neuropathy-a-randomized-controlled-trial
#8
Mats De Jaeger, Lisa Goudman, Peter Van Schuerbeek, Johan De Mey, Bart Keymeulen, Raf Brouns, Maarten Moens
INTRODUCTION: With the development of new neuroimaging tools it has become possible to assess neurochemical alterations in patients experiencing chronic pain and to determine how these factors change during pharmacological treatment. The goal of this study was to examine the exact neurochemical mechanism underlying pregabalin treatment, utilizing magnetic resonance spectroscopy (1 H-MRS), in a population of patients with painful diabetic polyneuropathy (PDN), with the overall aim to ultimately objectify the clinical effect of pregabalin...
June 27, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29936573/efficacy-and-safety-of-sitagliptin-in-hispanic-latino-patients-with-type-2-diabetes-a-pooled-analysis-from-ten-randomized-placebo-controlled-phase-3-clinical-trials
#9
Annaswamy Raji, Jianmin Long, Raymond L H Lam, Edward A O'Neill, Samuel S Engel
INTRODUCTION: To assess the efficacy and safety profile of the dipeptidyl-peptidase-4 inhibitor sitagliptin in a population of self-identified Hispanic/Latino patients with type 2 diabetes. METHODS: Data were pooled from ten randomized, double-blind studies in which subjects were treated with sitagliptin 100 mg/day (as mono- or combination therapy) or placebo, and used to evaluate the glycemic efficacy, safety, and tolerability of sitagliptin compared with placebo after 24 weeks of treatment...
June 23, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29934758/diabetic-gastroparesis-principles-and-current-trends-in-management
#10
REVIEW
Sathya Krishnasamy, Thomas L Abell
This article is a comprehensive review of diabetic gastroparesis, defined as delayed or disordered gastric emptying, including basic principles and current trends in management. This review includes sections on anatomy and physiology, diagnosis and differential diagnosis as well as management and current guidelines for treatment of diabetic gastroparesis. Diabetic gastroparesis (DGp) is a component of autonomic neuropathy resulting from long-standing poorly controlled type 1 and type 2 diabetes. The diagnostic workup of DGp first excludes obstruction and other causes including medications that may mimic delayed/disordered gastric emptying...
June 22, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29931507/correction-to-comparison-of-adipose-distribution-indices-with-gold-standard-body-composition-assessments-in-the-empa-reg-h2h-su-trial-a-body-composition-sub-study
#11
Ian J Neeland, Darren K McGuire, Björn Eliasson, Martin Ridderstråle, Cordula Zeller, Hans J Woerle, Uli C Broedl, Odd Erik Johansen
In the original publication, disclosure statement for the author Ian J. Neeland was published incorrectly. The correct statement should read as "Ian J. Neeland received financial assistance for publishing/article processing fees from Boehringer Ingelheim".
June 21, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29931506/there-is-a-close-association-between-the-recovery-of-liver-injury-and-glycemic-control-after-sglt2-inhibitor-treatment-in-japanese-subjects-with-type-2-diabetes-a-retrospective-clinical-study
#12
Tomoe Kinoshita, Masashi Shimoda, Junpei Sanada, Yoshiro Fushimi, Yurie Hirata, Shintaro Irie, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Kenji Kohara, Fuminori Tatsumi, Shinji Kamei, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
INTRODUCTION: Sodium-glucose co-transporter 2 (SGLT2) inhibitors function not only to reduce hyperglycemia but also to ameliorate liver injury and reduce body weight. The aim of this study was to examine in which subjects SGLT2 inhibitors are more effective for glycemic control, liver injury, and obesity in Japanese subjects with type 2 diabetes mellitus. METHODS: We enrolled a total of 156 subjects with type 2 diabetes who initiated SGLT2 inhibitor treatment after September 1, 2014 in Kawasaki Medical School (Protocol No...
June 21, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29926400/ipragliflozin-add-on-therapy-to-a-glp-1-receptor-agonist-in-japanese-patients-with-type-2-diabetes-agate-a-52-week-open-label-study
#13
Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, Taishi Sakatani
INTRODUCTION: Few data are available regarding ipragliflozin treatment in combination with glucagon-like peptide-1 (GLP-1) receptor agonists. The aim of this study was to evaluate the efficacy and safety of ipragliflozin in combination with GLP-1 receptor agonists in Japanese patients with inadequately controlled type 2 diabetes mellitus (T2DM). METHODS: This multicenter study (consisting of three periods: a 4-week washout period, a 6-week observation period, and a 52-week open-label treatment period) included patients aged ≥ 20 years who received a stable dose/regimen of a GLP-1 receptor agonist either solely or in combination therapy with a sulfonylurea for ≥ 6 weeks, with glycosylated hemoglobin (HbA1c) of ≥ 7...
June 20, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29909478/correction-to-reproducibility-and-validity-of-a-questionnaire-measuring-treatment-burden-on-patients-with-type-2-diabetes-diabetic-treatment-burden-questionnaire-dtbq
#14
Hitoshi Ishii, Koki Shin, Takahiro Tosaki, Tatsuya Haga, Yoshiki Nakajima, Toshihiko Shiraiwa, Nobuaki Watanabe, Miyuki Koizumi, Hiroki Nakajima, Sadanori Okada, Tsuyoshi Mashitani, Takako Mohri, Yasuhiro Akai
In the original publication, second author's name was incorrectly published as Hiroki Shin. The correct name should read as 'Koki Shin'.
June 16, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29907893/semaglutide-s-c-once-weekly-in-type-2-diabetes-a-population-pharmacokinetic-analysis
#15
Kristin Cecilie Carlsson Petri, Steen Hvass Ingwersen, Anne Flint, Jeppe Zacho, Rune Viig Overgaard
INTRODUCTION: Semaglutide, a new treatment option approved for the treatment of patients with type 2 diabetes mellitus, is a glucagon-like peptide-1 receptor agonist to be injected subcutaneously once weekly. This analysis used a population pharmacokinetic model of semaglutide to identify clinically relevant covariates for exposure. METHODS: A total of 1612 patients with up to seven pharmacokinetic observations each were included in the analysis. All subjects had type 2 diabetes mellitus and were enrolled in one of five trials in the phase III development program for subcutaneous semaglutide once weekly (the SUSTAIN program)...
June 15, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29949016/a-randomized-controlled-trial-of-dapagliflozin-plus-once-weekly-exenatide-versus-placebo-in-individuals-with-obesity-and-without-diabetes-metabolic-effects-and-markers-associated-with-bodyweight-loss
#16
Maria J Pereira, Per Lundkvist, Prasad G Kamble, Joey Lau, Julian G Martins, C David Sjöström, Volker Schnecke, Anna Walentinsson, Eva Johnsson, Jan W Eriksson
INTRODUCTION: The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and complementary mechanisms. This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly (QW) among adults with obesity and without diabetes. METHODS: In the primary trial, adults with obesity and without diabetes [n = 50; 18-70 years; body mass index (BMI) 30-45 kg/m2 ] were randomized to double-blind oral dapagliflozin 10 mg (DAPA) once daily plus subcutaneous long-acting exenatide 2 mg QW (ExQW) or placebo over 24 weeks, followed by an open-label extension from 24-52 weeks during which all participants received active treatment...
June 13, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29949015/long-term-effect-of-the-color-record-method-in-self-monitoring-of-blood-glucose-on-metabolic-parameters-in-type-2-diabetes-a-2-year-follow-up-of-the-color-impact-study
#17
Akiko Nishimura, Shin-Ichi Harashima, Kiminori Hosoda, Nobuya Inagaki
INTRODUCTION: This article evaluates the potential long-term effect of two different color indication methods for self-monitoring of blood glucose (SMBG), the color record (CR) and color display (CD), on metabolic parameters in insulin-treated type 2 diabetes in a post-intervention period. METHODS: 101 participants with type 2 diabetes who completed the Color IMPACT study were enrolled in a 2-year comparison follow-up study. Participants continued SMBG with their usual diabetes care...
June 12, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29949014/cardiovascular-safety-of-empagliflozin-versus-dipeptidyl-peptidase-4-dpp-4-inhibitors-in-type-2-diabetes-systematic-literature-review-and-indirect-comparisons
#18
Chakrapani Balijepalli, Rohan Shirali, Prashanth Kandaswamy, Anastasia Ustyugova, Egon Pfarr, Søren S Lund, Eric Druyts
INTRODUCTION: Clinical trials conducted in patients with type 2 diabetes (T2DM) treated with glucose-lowering drugs and examining cardiovascular-related outcomes have yielded mixed results. In this work, we aimed to assess the relative treatment effects of empagliflozin versus sitagliptin and saxagliptin (dipeptidyl peptidase-4 (DPP-4) inhibitors) on cardiovascular-related outcomes in patients with T2DM. METHODS: We conducted a systematic literature review to identify clinical trials assessing cardiovascular-related outcomes for sitagliptin-, saxagliptin-, and empagliflozin-treated patients with T2DM...
June 12, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29869049/diabetes-fatigue-syndrome
#19
EDITORIAL
Sanjay Kalra, Rakesh Sahay
In this editorial we propose a condition that we refer to as 'diabetes fatigue syndrome' (DFS), which is commonly encountered in clinical practice. We define DFS as a multifactorial syndrome of fatigue or easy fatigability that occurs in persons with diabetes. It may be caused by a variety of lifestyle, nutritional, medical, psychological, glycemia/diabetes-related, and endocrine and iatrogenic factors. The authors share clinical pearls which can help the diabetes healthcare provider diagnose DFS, identify its etiologic factors and manage the syndrome...
June 4, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29858976/comparative-effectiveness-of-dpp-4-inhibitors-versus-sulfonylurea-for-the-treatment-of-type-2-diabetes-in-routine-clinical-practice-a-retrospective-multicenter-real-world-study
#20
Gian Paolo Fadini, Daniele Bottigliengo, Federica D'Angelo, Franco Cavalot, Antonio Carlo Bossi, Giancarlo Zatti, Ileana Baldi, Angelo Avogaro
INTRODUCTION: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. METHODS: This was a multicenter retrospective study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide extended release. The primary endpoint was change from baseline in HbA1c. Secondary endpoints were changes in fasting plasma glucose, body weight, and systolic blood pressure...
June 1, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
journal
journal
43222
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"